Literature DB >> 221531

Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism.

J Shepherd, C J Packard, J R Patsch, A M Gotto, O D Taunton.   

Abstract

This report describes the effects of pharmacologic doses (3 g/d) of nicotinic acid on the plasma distribution and chemical composition of the high density lipoprotein (HDL) subfractions HDL(2) and HDL(3) and examines the influence of the drug on the metabolism of the major HDL apoproteins, apolipoproteins A-I (ApoA-I) and A-II (Apo-II). The drug lowered plasma cholesterol (15%, P < 0.05) and triglyceride (27%, P < 0.01); the former effect a result of a fall in the amount of cholesterol associated with very low density lipoproteins (31%, P < 0.02) and low density lipoproteins (36%, P < 0.02). Conversely, it raised plasma HDL cholesterol (23%, P < 0.05) and increased (by 345%) the plasma HDL(2):HDL(3) ratio. The latter derived from an absolute increment (646%) in circulating HDL(2), coupled with a fall (47%) in HDL(3). This change was not associated with major alterations in the overall cholesterol (free and esterified), triglyceride, phospholipid, or protein content of the subfractions; however, it was accompanied by substantial changes in their protein composition. In particular, the molar ratio of ApoA-I:ApoA-II in HDL(3) declined from 2.7:1 to 2.1:1 during nicotinic acid treatment.Significant perturbations of ApoA-I and ApoA-II metabolism accompanied the drug-induced HDL subfraction redistribution. Specifically, the plasma concentration of ApoA-I rose by 7% (P < 0.05) because of a decrease in its fractional catabolic rate. Moreover, whereas before treatment 6 and 94% of the plasma ApoA-I circulated with HDL(2) and HDL(3), after commencement of nicotinic acid therapy this distribution became 49 and 51% in HDL(2) and HDL(3), respectively. ApoA-II was found mainly in HDL(3), both before and during nicotinic acid treatment. Administration of the drug caused a 14% reduction in its plasma concentration (P < 0.05), which derived principally from a fall (22%, P < 0.01) in its synthetic rate. These data suggest that the effects of nicotinic acid on the HDL subfraction distribution may be mediated via (a) net transfer of ApoA-I from HDL(3) to HDL(2) and (b) a reduction in ApoA-II synthesis. Our present understanding of the association between HDL and atherosclerosis indicates that such changes may have prophylactic value in the prevention of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221531      PMCID: PMC372026          DOI: 10.1172/JCI109385

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  THE INHERITANCE OF HIGH DENSITY LIPOPROTEIN DEFICIENCY (TANGIER DISEASE).

Authors:  D S FREDRICKSON
Journal:  J Clin Invest       Date:  1964-02       Impact factor: 14.808

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Influence of nicotinic acid on serum cholesterol in man.

Authors:  R ALTSCHUL; A HOFFER; J D STEPHEN
Journal:  Arch Biochem Biophys       Date:  1955-02       Impact factor: 4.013

4.  Epidemiology of coronary heart disease. Implications for the practicing physician.

Authors:  W B KANNEL; A KAGAN; T R DAWBER; N REVOTSKIE
Journal:  Geriatrics       Date:  1962-10

5.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

6.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

7.  The in vitro interaction of human apolipoprotein A-I and high density lipoproteins.

Authors:  J Shepherd; A M Gotto; O D Taunton; M J Caslake; E Farish
Journal:  Biochim Biophys Acta       Date:  1977-12-21

8.  Metabolism of apolipoproteins A-I and A-II and its influence on the high density lipoprotein subfraction distribution in males and females.

Authors:  J Shepherd; C J Packard; J R Patsch; A M Gotto; O D Taunton
Journal:  Eur J Clin Invest       Date:  1978-06       Impact factor: 4.686

9.  The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study.

Authors:  N E Miller; D S Thelle; O H Forde; O D Mjos
Journal:  Lancet       Date:  1977-05-07       Impact factor: 79.321

10.  HIGH-DENSITY LIPOPROTEIN CONCENTRATIONS IN MEN AND WOMEN.

Authors:  M BARCLAY; R K BARCLAY; V P SKIPSKI
Journal:  Nature       Date:  1963-10-26       Impact factor: 49.962

View more
  36 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.

Authors:  Zoltán Benyó; Andreas Gille; Jukka Kero; Marion Csiky; Marie Catherine Suchánková; Rolf M Nüsing; Alexandra Moers; Klaus Pfeffer; Stefan Offermanns
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

4.  Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.

Authors:  Parag H Joshi; Peter P Toth; Seth T Lirette; Michael E Griswold; Joseph M Massaro; Seth S Martin; Michael J Blaha; Krishnaji R Kulkarni; Arif A Khokhar; Adolfo Correa; Ralph B D'Agustino; Steven R Jones
Journal:  Eur J Prev Cardiol       Date:  2014-07-25       Impact factor: 7.804

Review 5.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

6.  Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.

Authors:  Milada Dobiásová; Jiri Frohlich; Michaela Sedová; Marian C Cheung; B Greg Brown
Journal:  J Lipid Res       Date:  2011-01-11       Impact factor: 5.922

7.  Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.

Authors:  Stefania Lamon-Fava; Margaret R Diffenderfer; P Hugh R Barrett; Aaron Buchsbaum; Mawuli Nyaku; Katalin V Horvath; Bela F Asztalos; Seiko Otokozawa; Masumi Ai; Nirupa R Matthan; Alice H Lichtenstein; Gregory G Dolnikowski; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

Review 8.  Niacin, lipids, and heart disease.

Authors:  Shaista Malik; Moti L Kashyap
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 9.  Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.

Authors:  Klaus G Parhofer
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

Review 10.  Gene activation regresses atherosclerosis, promotes health, and enhances longevity.

Authors:  Pauli V Luoma
Journal:  Lipids Health Dis       Date:  2010-07-06       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.